• +1-646-491-9876
    • +91-20-67278686

    Search

    Ventilator Associated Pneumonia Pipeline Review H2 2017

    Ventilator Associated Pneumonia Pipeline Review H2 2017

    • Report Code ID: RW0001884150
    • Category Pharmaceuticals
    • No. of Pages 143
    • Publication Month Jul-17
    • Publisher Name Global Markets Direct
    Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2017, provides an overview of the Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline landscape.

    Ventilator-associated pneumonia (VAP) is pneumonia that develops 48 hours or longer after mechanical ventilation is given by means of an endotracheal tube or tracheostomy. Ventilator-associated pneumonia (VAP) results from the invasion of the lower respiratory tract and lung parenchyma by microorganisms. The most important signs are fever, low body temperature, new purulent sputum, and hypoxemia (decreasing amounts of oxygen in the blood) .

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Ventilator Associated Pneumonia (VAP) - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Ventilator Associated Pneumonia (VAP) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 7, 9, 5, 11, 1 and 1 respectively.

    Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Ventilator Associated Pneumonia (VAP) (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Ventilator Associated Pneumonia (VAP) (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Ventilator Associated Pneumonia (VAP) (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Ventilator Associated Pneumonia (VAP) (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Ventilator Associated Pneumonia (VAP) (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 4
    Introduction 5
    Publisher Report Coverage 5
    Ventilator Associated Pneumonia (VAP) - Overview 6
    Ventilator Associated Pneumonia (VAP) - Therapeutics Development 7
    Pipeline Overview 7
    Pipeline by Companies 8
    Products under Development by Companies 11
    Ventilator Associated Pneumonia (VAP) - Therapeutics Assessment 13
    Assessment by Target 13
    Assessment by Mechanism of Action 15
    Assessment by Route of Administration 17
    Assessment by Molecule Type 19
    Ventilator Associated Pneumonia (VAP) - Companies Involved in Therapeutics Development 21
    Achaogen Inc 21
    Adenium Biotech ApS 21
    Aridis Pharmaceuticals LLC 22
    AstraZeneca Plc 22
    Bayer AG 23
    Cardeas Pharma Corp 23
    Destiny Pharma Ltd 24
    Dong-A Socio Holdings Co Ltd 24
    Lakewood-Amedex Inc 25
    MedImmune LLC 25
    Meiji Seika Pharma Co Ltd 26
    Merck & Co Inc 26
    Motif Bio Plc 27
    Nabriva Therapeutics AG 27
    Polyphor Ltd 28
    Shionogi & Co Ltd 28
    Tetraphase Pharmaceuticals Inc 29
    The Medicines Company 29
    Theravance Biopharma Inc 30
    Wockhardt Ltd 30
    Zavante Therapeutics Inc 31
    Ventilator Associated Pneumonia (VAP) - Drug Profiles 32
    (amikacin sulfate + fosfomycin) - Drug Profile 32
    (avibactam + ceftazidime) - Drug Profile 34
    (avibactam sodium + aztreonam lysine) - Drug Profile 39
    (cefepime + zidebactam) - Drug Profile 41
    (ceftolozane sulfate + tazobactam sodium) - Drug Profile 42
    (cilastatin sodium + imipenem + relebactam) - Drug Profile 47
    (meropenem+ vaborbactam) - Drug Profile 49
    AA-139 - Drug Profile 53
    Aerucin - Drug Profile 54
    amikacin sulfate - Drug Profile 56
    arbekacin - Drug Profile 58
    ASN-100 - Drug Profile 59
    cefiderocol - Drug Profile 62
    EBX-004 - Drug Profile 66
    eravacycline - Drug Profile 67
    exeporfinium chloride - Drug Profile 74
    fosfomycin tromethamine - Drug Profile 76
    iclaprim mesylate - Drug Profile 79
    lefamulin acetate - Drug Profile 84
    Mul-1867 - Drug Profile 89
    murepavadin - Drug Profile 91
    Nu-2 - Drug Profile 93
    Nu-3 - Drug Profile 94
    Panaecin - Drug Profile 96
    panobacumab - Drug Profile 97
    plazomicin sulfate - Drug Profile 99
    POL-7001 - Drug Profile 107
    Qn-2251 - Drug Profile 108
    sodium hypochlorite - Drug Profile 109
    suvratoxumab - Drug Profile 110
    tedizolid phosphate - Drug Profile 111
    telavancin hydrochloride - Drug Profile 119
    tosatoxumab - Drug Profile 124
    Viritron VDX - Drug Profile 126
    Ventilator Associated Pneumonia (VAP) - Dormant Projects 127
    Ventilator Associated Pneumonia (VAP) - Discontinued Products 128
    Ventilator Associated Pneumonia (VAP) - Product Development Milestones 129
    Featured News & Press Releases 129
    Appendix 139
    Methodology 139
    Coverage 139
    Secondary Research 139
    Primary Research 139
    Expert Panel Validation 139
    Contact Us 139
    Disclaimer 140

    List of Tables

    Number of Products under Development for Ventilator Associated Pneumonia (VAP) , H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Products under Development by Companies, H2 2017
    Products under Development by Companies, H2 2017 (Contd..1) , H2 2017
    Number of Products by Stage and Target, H2 2017
    Number of Products by Stage and Mechanism of Action, H2 2017
    Number of Products by Stage and Route of Administration, H2 2017
    Number of Products by Stage and Molecule Type, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Achaogen Inc, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Adenium Biotech ApS, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Aridis Pharmaceuticals LLC, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by AstraZeneca Plc, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Bayer AG, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Cardeas Pharma Corp, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Destiny Pharma Ltd, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Lakewood-Amedex Inc, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by MedImmune LLC, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Merck & Co Inc, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Motif Bio Plc, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Nabriva Therapeutics AG, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Polyphor Ltd, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Shionogi & Co Ltd, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by The Medicines Company, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Theravance Biopharma Inc, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Wockhardt Ltd, H2 2017
    Ventilator Associated Pneumonia (VAP) - Pipeline by Zavante Therapeutics Inc, H2 2017
    Ventilator Associated Pneumonia (VAP) - Dormant Projects, H2 2017
    Ventilator Associated Pneumonia (VAP) - Discontinued Products, H2 2017

    List of Figures

    Number of Products under Development for Ventilator Associated Pneumonia (VAP) , H2 2017
    Number of Products under Development by Companies, H2 2017
    Number of Products by Top 10 Targets, H2 2017
    Number of Products by Stage and Top 10 Targets, H2 2017
    Number of Products by Top 10 Mechanism of Actions, H2 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
    Number of Products by Top 10 Routes of Administration, H2 2017
    Number of Products by Stage and Top 10 Routes of Administration, H2 2017
    Number of Products by Molecule Types, H2 2017
    Number of Products by Stage and Molecule Types, H2 2017
    Achaogen Inc
    Adenium Biotech ApS
    Aridis Pharmaceuticals LLC
    AstraZeneca Plc
    Bayer AG
    Cardeas Pharma Corp
    Destiny Pharma Ltd
    Dong-A Socio Holdings Co Ltd
    Lakewood-Amedex Inc
    MedImmune LLC
    Meiji Seika Pharma Co Ltd
    Merck & Co Inc
    Motif Bio Plc
    Nabriva Therapeutics AG
    Polyphor Ltd
    Shionogi & Co Ltd
    Tetraphase Pharmaceuticals Inc
    The Medicines Company
    Theravance Biopharma Inc
    Wockhardt Ltd
    Zavante Therapeutics Inc

    Request for Sample

    Report Url https://www.reportsweb.com//ventilator-associated-pneumonia-pipeline-review-h2-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//ventilator-associated-pneumonia-pipeline-review-h2-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//ventilator-associated-pneumonia-pipeline-review-h2-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments